COVID-19-Related Celltrion Group announced Phase I results from its antibody cocktail of Regkirona and CT-P63. One Phase I study tested CT-P63 in 24 healthy participants in Poland. The trial hit the primary objective of safety and tolerability. It also demonstrated strong neutralizing activity against the Omicron variant. CT-P63 is a monoclonal antibody that targets the SARS-CoV-2 spike […]

Within hours of the news that the J.P. Morgan (JPM) Healthcare Conference would be held virtually in 2022, hotel prices in San Francisco plummeted from thousands of dollars per night to a few hundred for the same rooms. Some 24 hours later, Biotech Showcase – a premier partnering event for small biotech companies – also announced its […]

The FolRα-targeted antibody-drug conjugate (ADC) STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer, according to interim data from the dose-expansion portion of the phase 1 STRO-002-GM1 trial (NCT03748186).1 As of the interim data cutoff date of November 8, 2021, the ADC produced an objective response rate (ORR) of […]